Santarus Pharming, Announce New Data from Open-Label Repeat Treatment Study with RUCONEST
November 08, 2013 at 05:55 AM EST
Santarus (NASDAQ: SNTS ) and Pharming Group NV (OTC: PHGUF ) announced that new data from an open-label extension of the pivotal Phase III clinical study with RUCONEST® (recombinant human C1 esterase
